• Home
  • Practice Speciality
    • MedSpa
    • EyeCare
    • Oncology
    • Rhuematology
    • Dispensary / Pharmacy
    • Primary Care
  • What We Do
  • Video's Blog & Articles
  • Contact US
  • Snapshot
  • More
    • Home
    • Practice Speciality
      • MedSpa
      • EyeCare
      • Oncology
      • Rhuematology
      • Dispensary / Pharmacy
      • Primary Care
    • What We Do
    • Video's Blog & Articles
    • Contact US
    • Snapshot
  • Home
  • Practice Speciality
    • MedSpa
    • EyeCare
    • Oncology
    • Rhuematology
    • Dispensary / Pharmacy
    • Primary Care
  • What We Do
  • Video's Blog & Articles
  • Contact US
  • Snapshot

Video

You May Already Be a Dispenser And That Changes Your Risk

LinkedIn Post 4/23

LinkedIn Post 4/14

LinkedIn Post 4/1

LinkedIn Post 3/31

Proof not Promises

For years, DSCSA enforcement focused upstream manufacturers and wholesalers.


That phase is complete.


FDA inspections are now evaluating medical practices that purchase, store, and administer Rx products in-office. And they’re asking for documented proof of sourcing, traceability, and reconciliation.

This isn’t theoretical. It’s operational.

New York Just Inspected 223 MedSpas. Is Yours Next?

The New York Department of State just completed a statewide sweep of MedSpa providers 87 violations, suspended licenses, and revoked credentials. If your practice administers Botox, fillers, or any injectable, here is what you need to know about your drug supply chain before someone shows up at your door.

The FDA just changed how inspections work and most practices won’t see it coming.

They don’t need to walk into your office anymore.
With finalized guidance on Remote Regulatory Assessments (RRAs), FDA can now:
• Request your SOPs, purchasing records, and inventory logs
• Review your DSCSA documentation
• Evaluate your compliance remotely
• Decide next steps — without ever stepping onsite

No time to “get ready.”

Here’s the shift most people are missing:

Your documentation is now your inspection.
If it’s incomplete, informal, or inconsistent that’s exactly what FDA sees.
And that’s what they act on.

Current Blogs and Articles

PDF Viewer

Remote Regulatory Assessment

Download PDF

Downloads

Turbare Manufacturing WARNING LETTER (pdf)Download
Sterling Distributors WARNING LETTER (pdf)Download
exec_summary_rheumatology (pdf)Download
exec_summary_primarycare (pdf)Download
exec_summary_oncology (pdf)Download
exec_summary_mid (pdf)Download
A Wrinkle in the Supply Chain (pdf)Download
rra_brief_claritas (pdf)Download
exec_summary_medspa_v2 (pdf)Download
  • Video's Blog & Articles
  • Snapshot

Claritas Axis

Copyright © 2026 claritasaxis.com - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept